Bayer files for second regorafenib use in Japan, GIST
This article was originally published in Scrip
Bayer is wasting no time in expanding the planned indications for regorafenib in Japan, filing an approval application for use in metastatic and/or unresectable gastrointestinal stromal tumors (GIST) within six months of that for colorectal cancer.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.